Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://link.springer.com/doi/10.1007/BF02246075 below:

Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives

In the context of animal studies of hallucinogens, an LSD-false positive is defined as a drug known to be devoid of hallucinogenic activity in humans but which nonetheless fully mimics LSD in animals. Quipazine, MK-212, lisuride, and yohimbine have all been reported to be LSD false positives. The present study was designed to determine whether these compounds also substitute for the stimulus effects of the more pharmacologically selective hallucinogen (−)DOM (0.56 mg/kg, 75-min pretreatment time). The LSD and (−)DOM stimuli fully generalized to quipazine (3.0 mg/kg) and lisuride (0.2 mg/kg), but only partially generalized to MK-212 (0.1–1.0 mg/kg) and yohimbine (2–20 mg/kg). In combination tests, pirenpirone (0.08 mg/kg), a compound with both D₂ and 5-HT_2A affinity, blocked the substitution of quipazine and lisuride for the (−)DOM stimulus. Ketanserin (2.5 mg/kg), an antagonist with greater than 1 order of magnitude higher affinity for 5-HT_2A receptors than either 5-HT_2C or D₂ receptors, also fully blocked the substitution of these compounds for the (−)DOM stimulus, while the selective D₂ antagonist thiothixene (0.1–1.0 mg/kg) failed to block the substitution of lisuride for the (−)DOM stimulus. These results suggest that quipazine and lisuride substitute for the stimulus properties of the phenylalkglamine hallucinogen (−)DOM via agonist activity at 5-HT_2A receptors. In addition, these results suggest that 5-HT_2A agonist activity may be required, but is not in itself sufficient, for indolamine and phenylalkglamine compounds to elicit hallucinations in humans. Finally, it is concluded that MK-212 and yohimbine are neither LSD nor (−)DOM false positives.

This is a preview of subscription content, log in via an institution to check access.

Springer+ Basic

€34.99 /Month

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

• Appel JB, Cunningham KA (1986) The use of drug discrimination procedures to characterize hallucinogenic drug actions. Psychopharmacol Bull 22:959–967

  Google Scholar 

• Appel JB, White FJ, Holohean AM (1982) Analyzing mechanisms of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6:529–536

  Google Scholar 

• Ator NA, Griffiths RR (1989) Asymmetrical cross-generalization in drug discrimination with lorazepam and pentobarbital training conditions Drug Dev Res 16:355–364

  Google Scholar 

• Burris KD, Breeding M, Sanders-Bush E (1991) (+)Lysergic acid diethylamide, but not its non-hallucinogenic congeners, is a potent serotonin 5-HT_1C receptor agonist. J Pharmacol Exp Ther 258:891–896

  Google Scholar 

• Burt PR, Creese I, Snyder SH (1976) Binding interactions of lysergic acid diethylamide and related agents with dopaminergic receptors in brain. Mol Pharmacol 12:631–638

  Google Scholar 

• Colpaert FC (1984) Cross generalization with LSD and yohimbine in the rat. Eur J Pharmacol 102:541–544

  Google Scholar 

• Colpaert FC, Niemegeers CJE, Jansen PAJ (1979) In vivo evidence of partial agonist activity exerted by purported 5-HT antagonists. Eur J Pharmacol 58:505–509

  Google Scholar 

• Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT₂ and 5-HT_1C) receptors. J Pharmacol Exp Ther 242:552–557

  Google Scholar 

• Creese I, Burt, DA, Snyder SH (1976) The dopamine receptor: differential binding ofd-LSD and related agents to agonist and antagonist states. Life Sci 17:1715–1720

  Google Scholar 

• Cunningham KA, Appel JB (1987) Neuropharmacological reassessment of the discriminative stimulus properties of lysergic acid diethylamide (LSD) Psychopharmacology 91:67–73

  Google Scholar 

• Cunningham KA, Callahan PM, Appel JB (1986) Discriminative stimulus properties of the serotonin agonist MK-212. Psychopharmacology 90:193–197

  Google Scholar 

• Fiorella D, Rabin RA, Winter JC (1995a) The role of the 5-HT_2A and 5-HT_2C receptors in the stimulus effects ofm-chlorophenyl-piperazine. Psychopharmacology (in press)

• Fiorella D, Palumbo PA, Rabin RA, Winter JC (1995b) The time dependent stimulus effects of (−)2,5-dimethyoxy-4-methylamphetamine: implications for drug-induced stimulus control as a method for the study of hallucinogenic drugs. Psychopharmacology (in press)

• Fiorella D, Rabin RA, Winter JC (1995c) The role of the 5-HT_2A and 5- HT_2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology (in press)

• Freedman DX, Boggan WO (1982) Biochemical pharmacology of psychotomimetics. In: Hoffmeister F, Stile G (eds) Psychotropic agents: handbook of experimental pharmacology, vol. 55, part 3. Springer, Berlin, pp 57–88

  Google Scholar 

• Glennon RA (1990) Do hallucinogens act as 5-HT₂ agonists or antagonists? Neuropsychopharmacology 3:509–517

  Google Scholar 

• Glennon RA, Rosecrans JA, Young R (1982) The use of the drug discrimination paradigm for studying hallucinogenic agents. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical Press, Amsterdam, pp 69–96

  Google Scholar 

• Glennon RA, Rosecrans JA, Young R (1984) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–376

  Google Scholar 

• Hirshhorn ID, Winter JC (1971) Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli. Psychopharmacologia 22:64–71

  Google Scholar 

• Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacology 2:93–106

  Google Scholar 

• Hoyer D (1988) Functional correlates of serotonin 5-HT₁ recognition sites. J Recept Res 8:59–81

  Google Scholar 

• Kennis EJ, Vandenberk J, Boey JM, Mertens JC, Van Heertum AHM, Janssen M, Awouters F (1986) The chemical development of selective and specific serotonin S₂-antagonists. Drug Dev Res 8:113–140

  Google Scholar 

• Leysen JE (1985) Serotonin receptor binding sites. In: Green AR (ed) Neuropharmacology of serotonin. Oxford University Press, Oxford, pp 86–87

  Google Scholar 

• Leysen JE, Janssen PFM, Niemegeers CJE (1989) Rapid desensitization and down-regulation of 5-HT₂ receptors by DOM treatment. Eur J Pharmacol 163:145–149

  Google Scholar 

• Lowy MT, Meltzer HY (1988) Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biol Psychiatry 23:818–828

  Google Scholar 

• Maj J, Pawlowski L, Sarnek J (1974) The role of brain 5-hydroxytryptamine in the central action ofL-DOPA. In: Costa E, Gessa GL, Sandler M (eds) Serotonin — new vistas. Raven Press, New York, pp 253–256

  Google Scholar 

• Meibach RC, Maayani S, Green JP (1980) Characterization and radioautography of (³H)LSD binding by rat brain slices in vitro: the effect of 5-hydroxytryptamine. Eur J Pharmacol 67:371–382

  Google Scholar 

• Meltzer HY, Shigehiro M, Lee JC (1989) The ratios of serotonin and dopamine affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390–392

  Google Scholar 

• Parati EA, Zanardi P, Cocchi J, Muller EE (1980) Neuroendocrine effects of quipazine in man in healthy state or with neurological disorders. J Neural Transm 47:293–297

  Google Scholar 

• Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924–928

  Google Scholar 

• Shulgin A (1973) Stereospecific requirements for hallucinogens. J Pharm Pharmacol 25:271–272

  Google Scholar 

• Shulgin A, Shulgin A (1991) The chemical story. In: Joy D (ed) PIHKAL. Transform Press, Berkeley, CA, pp 453–924

  Google Scholar 

• Silverman PB, Ho BT (1978) Stimulus properties of DOM: commonality with other hallucinogens. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier, North Holland Biomedical Press, Amsterdam, pp 189–198

  Google Scholar 

• Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT₂ receptors as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213–216

  Google Scholar 

• U'Prichard DC, Greenberg DA, Snyder SH (1977) Binding characteristics of radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol 13:454–473

  Google Scholar 

• Van Wijngaarden I, Tulp MTM, Soudijin W (1990) The concept of selectivity in 5-HT research. Eur J Pharmacol 188:301–312

  Google Scholar 

• White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol Biochem Behav 24:365–369

  Google Scholar 

• White FJ, Appel JB (1982a) The role of dopamine and serotonin in the discriminative stimulus effects of lisuride. J Pharmacol Exp Ther 221:421–427

  Google Scholar 

• White FJ, Appel JB (1982b) Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. Science 216:535–537

  Google Scholar 

• White FJ, Appel JB (1982c) Training dose as a factor in LSD-saline discrimination. Psychopharmacology 76:20–25

  Google Scholar 

• Winter JC (1978a) Drug-induced stimulus control. In: Blackman D, Sanger J (eds) Contemporary research in behavioral pharmacology. Plenum Press, New York, pp 209–238

  Google Scholar 

• Winter JC (1978b) Yohimbine-induced stimulus control in the rat. Arch Int Pharmacodyn Ther 235:86–92

  Google Scholar 

• Winter JC (1979) Quipazine-induced stimulus control in the rat. Psychopharmacology 60:265–269

  Google Scholar 

• Winter JC (1994) The stimulus effects of serotonergic hallucinogens in animals. In: Lin GC, Glennon RA (eds) Hallucinogens, an update. NIDA Monograph, US Government Printing Office, Washington DC, pp 157–182

  Google Scholar 

• Winter JC, Rabin RA (1993) The stimulus effects ofm-chlorophenylpiperazine in the rat. Pharmacol Biochem Behav 45:221–225

  Google Scholar 

Download references

1. Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA

   David Fiorella, R. A. Rabin & J. C. Winter

1. David Fiorella
2. R. A. Rabin
3. J. C. Winter

This study was supported in part by US Public Health Service grant DA 03385 (J.C.W., R.A.R.), by National Research Service Award MH 10567 (D.F.), and by a fellowship from Schering-Plough Research Institute (D.F.). Animals used in these studies were maintained in accordance with the “Guide for Care and Use of Laboratory Animals” of the Institute of Laboratory Animal Resources, National Research Council.

Fiorella, D., Rabin, R.A. & Winter, J.C. Role of 5-HT_2A and 5-HT_2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives. Psychopharmacology 121, 357–363 (1995). https://doi.org/10.1007/BF02246075

Download citation

• Received: 17 September 1994

• Revised: 09 December 1994

• Issue Date: October 1995

• DOI: https://doi.org/10.1007/BF02246075

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4